Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00857194 · ClinicalTrials.gov registry record

Cardiovascular Disease Study

A clinical trial of Spinal Cord Injury, sponsored by VA Office of Research and Development.

Completed
Registry status
170
Enrollment target
2
Study locations

NCT00857194: Completed study of Spinal Cord Injury, sponsored by VA Office of Research and Development.

NCT00857194 is a study of Spinal Cord Injury that has completed, run by VA Office of Research and Development. The registered enrollment target is 170 participants, above the 85-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (100% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00857194, a study of Spinal Cord Injury, has completed, sponsored by VA Office of Research and Development.

COMPLETED
Registry status
170 participants
Enrollment target
2
Study locations

Study Summary

Coronary heart disease (CHD) is a leading cause of death in the spinal cord injured (SCI) population, occurring at younger ages than in the able-bodied population. Conventional risk factors for CHD include high concentrations of low-density lipoprotein (LDL), low concentrations of high-density lipoprotein (HDL), diabetes mellitus (DM), smoking history, and family history. Other factors that may influence progression of CHD include C-reactive protein (an inflammatory marker), and fibrinogen (a pro-coagulant marker). Individuals with SCI with longer duration and greater completeness of injury are more likely to have significantly worse carbohydrate tolerance compared to other neurological deficit subgroups. Muscle atrophy after SCI is associated with increased insulin resistance. Prolonged inactivity has been shown to be associated with hyperinsulinemia and impaired glucose tolerance. Body composition changes after SCI to indicate significantly more total body fat mass and percent fat and less lean mass compared to able-bodied individuals. Carotid intima-media thickness is correlated with atherosclerosis progression and abdominal adiposity. Individuals with abdominal adiposity are at a higher risk for CHD, DM, hypertension, insulin resistance, and dyslipidemia. Abdominal adiposity and insulin resistance are contributors to postprandial lipemia, which may be a more sensitive indicator of CHD risk and progression. The purpose of this study is to determine the prevalence of conventional risk factors by assessing the 10-year risk for CHD, and identify emerging risk factors for CHD in the spinal cord injured population. Subjects will have the option to participate in a high fat meal test to determine postprandial lipemic responses. Knowledge of this information may be able to detect and prevent future cardiovascular events related to CHD.

Primary Outcome

Risk factors associated with coronary heart disease as follows: * Fasting Lipid Panel * Oral Glucose Tolerance Test * Blood Pressure * Body Anthropometrics * Family History

Conditions Studied

Interventions

  • PROCEDURE 2 hour Oral Glucose Tolerance Test
  • PROCEDURE Fat Meal Test

Study Locations (2)

New Jersey

  • Kessler Institute for Rehabilitation - West Orange

New York

  • James J. Peters VA Medical Center, Bronx, NY - The Bronx

Trial Details

FieldValue
Enrollment Target 170 participants
Start Date 2007-03-01
Est. Completion 2017-06-21
VA Office of Research and Development

1,668 total trials

What the finished NCT00857194 record still lists

NCT00857194 is an observational study that tracks outcomes without assigning an intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, above the 85-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (100% higher).

The record links to 1 condition, with Spinal Cord Injury appearing as the primary indexed condition, and to 2 interventions - of which 2 hour Oral Glucose Tolerance Test is the first listed.

NCT00857194 reports a single indexed study location in New Jersey, New York.

Frequently Asked Questions

What is clinical trial NCT00857194 about?

NCT00857194 is a clinical study titled "Cardiovascular Disease Study". Coronary heart disease (CHD) is a leading cause of death in the spinal cord injured (SCI) population, occurring at younger ages than in the able-bodied population. Conventional risk factors for CHD include high concentrations of low-density lipoprotein (LDL), low concentrations of high-density lipop...

What is the current status of trial NCT00857194?

This trial is currently completed. The enrollment target is 170 participants. The study started on 2007-03-01. Estimated completion is 2017-06-21.

What conditions does trial NCT00857194 study?

This clinical trial studies the following conditions: Spinal Cord Injury.

What interventions are being tested in trial NCT00857194?

The interventions under investigation include: 2 hour Oral Glucose Tolerance Test (PROCEDURE), Fat Meal Test (PROCEDURE).

Who is sponsoring clinical trial NCT00857194?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00857194 being conducted?

This trial has 2 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Spinal Cord Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00857194's enrollment target sits among peer trials

170 10th of 99 higher than 90 of 99 other Spinal Cord Injury trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Spinal Cord Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02016430 · 170 participants · NA

    Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)

  • NCT02621021 · 170 participants · Phase 2

    A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

  • NCT04094701 · 170 participants · NA

    Hip Arthroscopy Postoperative Opioid Demands

  • NCT04166409 · 170 participants · Phase 3

    A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00857194, the US trial registry maintained by the National Library of Medicine. NCT00857194 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.